Core Insights - The article emphasizes the focus on value investing in Asia, particularly in Hong Kong, targeting stocks with significant discrepancies between market price and intrinsic value, including deep value balance sheet bargains and wide moat stocks [1] Group 1: Investment Strategy - The research service aims to identify Asia-listed stocks that are undervalued, specifically looking for deep value balance sheet bargains such as net cash stocks and low price-to-book (P/B) ratio stocks [1] - The service also seeks wide moat stocks, which are characterized by strong competitive advantages and the ability to generate earnings power at a discount [1] Group 2: Market Focus - The primary focus is on the Hong Kong market, where the analyst has over a decade of experience in both buy and sell sides of equity markets [1] - Monthly updates and watch lists are provided to keep investors informed about potential investment opportunities [1]

Core Viewpoint - U.S. real estate stocks are experiencing volatility due to elevated mortgage rates, which are increasing borrowing costs and negatively impacting property valuations [2] Group 1: Market Conditions - The real estate sector has faced pressure from higher mortgage rates, leading to increased borrowing costs [2] - Property valuations are being weighed down as a result of these elevated borrowing costs [2] Group 2: Stock Performance - A list of ten real estate stocks has been compiled, ranked by their performance over the past month [2]

Core Concept - The article discusses the importance of understanding real risk tolerance during market volatility and introduces the concept of an "all-weather portfolio" as a strategy to manage risk effectively [1][2]. Group 1: All-Weather Portfolio Strategy - Ray Dalio advocates for an all-weather portfolio that goes beyond the traditional 60/40 stock-bond allocation, suggesting that incorporating commodities and inflation-indexed bonds can enhance risk management [5][6][7]. - The traditional 60/40 strategy, while popular, may not be sufficient in all market conditions, and Dalio emphasizes the need for diversification beyond just stocks and bonds [5][6]. Group 2: Investment Insights - Commodities, particularly gold, can perform well during inflationary periods, making them a valuable addition to a diversified portfolio [7]. - The emergence of inflation-indexed bonds presents new opportunities for investors, potentially leading to better portfolio outcomes compared to standard bonds [7].

Core Viewpoint - Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, significantly expanding its neuroscience portfolio into sleep medicine [1] Group 1: Acquisition Details - The acquisition deal is valued at up to $7.8 billion, indicating a major investment by Eli Lilly in enhancing its product offerings [1] - This move represents a strategic expansion into the sleep medicine sector, which is a growing area within the neuroscience field [1] Group 2: Implications for the Industry - The acquisition highlights the increasing focus on sleep disorders and related treatments within the pharmaceutical industry [1] - Eli Lilly's investment may signal a trend where major pharmaceutical companies seek to diversify their portfolios by entering niche markets like sleep medicine [1]

Core Insights - Agios Pharmaceuticals focuses on the discovery, development, and commercialization of innovative medicines for rare hematologic diseases, with its lead product being PYRUKYND (mitapivat) for hemolytic anemias [1] - The company reported a significant revenue increase for PYRUKYND, generating $20 million in quarterly revenue, an 86% increase year-over-year, and a full-year revenue of $54 million for 2025 [9] - Agios has approximately $1.2 billion in cash, providing a strong financial position to support its pipeline without immediate financing needs [9] Insider Transactions - Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer, sold 2,959 shares of common stock for about $82,000 on March 5, 2026, marking his first reported sale [5] - The sale was part of a standard procedure following the vesting of 8,100 restricted stock units (RSUs), with Krishnan selling approximately 37% of those shares to cover tax obligations [4][7] - Despite the sale, Krishnan retains 16,200 RSUs that have yet to vest, indicating substantial potential future exposure to the company [3][8] Future Prospects - Agios plans to pursue FDA accelerated approval for mitapivat in sickle cell disease, with a supplemental New Drug Application (sNDA) submission expected in the coming months, which could significantly expand the drug's market [9] - The company is positioned as a niche biotech with a real commercial product and a pipeline targeting rare blood disorders, appealing to investors interested in the rare disease or specialty pharma sectors [10]

Core Viewpoint - Banco de Chile (BCH) presents an attractive investment opportunity with a forward non-GAAP price-to-earnings multiple of 13.39x, which is favorable compared to its peers, Banco Santander-Chile at 11.59x and Bradesco at 6.95x [1] Group 1: Company Valuation - BCH's valuation indicates excellent value in the banking sector, particularly in comparison to other major banks in the region [1] - The bank's leading position in Chile's concentrated banking market enhances its investment appeal [1] Group 2: Analyst Perspective - The analysis emphasizes a focus on fundamental analysis, including valuation ratios and industry trends, to identify undervalued opportunities [1] - The research aims to provide insights that help investors make informed decisions based on solid fundamentals and value investing principles [1]

Core Insights - The stablecoin market is projected to grow five times, reaching a value of $2 trillion by 2028, driven by increased use cases and transaction velocity [1][5] - Stablecoin velocity has doubled over the past two years, with an average turnover of six times per month, indicating wider adoption [2][5] - Major companies and banks are developing their own stablecoins to enhance payment speed, reflecting a merger of traditional finance and blockchain technology [3][4] Market Dynamics - Originally, stablecoins were primarily used by traders and in decentralized finance, but their applications are expanding to include artificial intelligence payments and replacing traditional finance [4] - The current market value of stablecoins stands at $315.5 billion, according to DefiLlama data [5] - The report suggests that while new use cases are additive to overall transactions, increased velocity could potentially hinder growth if not accompanied by these new applications [5]

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased its American Depositary Shares during the specified class period, alleging misleading information regarding clinical study results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Mereo ADS from June 5, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against Mereo - The complaint claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Group 3: Company Background - Mereo BioPharma Group plc is a biopharmaceutical company based in London, focusing on treatments for rare diseases [2].

Core Insights - The article discusses the impact of "Liberation Day" on Wall Street, indicating a significant shift in investment strategies and market dynamics over the past year [1] Group 1 - Investors are facing new challenges in 2026, suggesting a need for adaptation in investment approaches [1]

Group 1 - The Annual Financial Report for Societe Generale SCF for the year ended December 31, 2025, has been filed with the French financial markets authority on March 31, 2026 [1] - The report is available to the public in French, free of charge, and can be accessed on the Societe Generale group's website and the AMF's website [2] - Societe Generale SCF is a specialized credit institution established under French law, authorized to operate as a SCF since December 20, 2007 [3] Group 2 - Societe Generale is a leading European bank with approximately 110,000 employees serving 27 million clients across 58 countries [4] - The bank has been providing a wide range of advisory and financial solutions for over 160 years, focusing on sustainable value creation for stakeholders [4] - The Group operates three complementary business segments, emphasizing ESG offerings and aims to be a leader in environmental transition and sustainability [5] Group 3 - The Group is included in major socially responsible investment indices, such as DJSI, FTSE4Good, and MSCI Low Carbon Leaders Index [5] - Societe Generale offers a variety of services including retail banking, private banking, insurance, and global banking solutions [8]